Data as of Q4 2025 (Dec 31, 2025)

MapLight Therapeutics, Inc.

(MPLT)

Financial Statements · SEC EDGAR XBRL

Net Income
-$161.2M
-107.7%
EPS
$-18.56
+82.4%
Op. Income
-$169.1M
-103.8%
FCF
-$138.6M
-74.2%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
$138.3M
$68.5M
$169.1M
$82.9M
-$169.1M
-$82.9M
$7.9M
$5.4M
-$161.2M
-$77.6M
$-18.56
$-105.38
$-18.56
$-105.38
8.7M
736K